{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T07:25:58Z","timestamp":1786865158173,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,16]]},"DOI":"10.7759\/cureus.114584","type":"journal-article","created":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T07:19:31Z","timestamp":1786864771000},"source":"Crossref","is-referenced-by-count":0,"title":["Evolving Role of Immunotherapy in Advanced Esophageal Squamous Cell Carcinoma: Are Programmed Death-Ligand 1 (PD-L1) Cutoffs Still Relevant?"],"prefix":"10.7759","author":[{"given":"Praloy","family":"Basu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray F","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024, 74:229-63. 10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s13000-023-01318-8","article-title":"Tumor Area Positivity (TAP) score of programmed death-ligand 1 (PD-L1): a novel visual estimation method for combined tumor cell and immune cell scoring","volume":"18","author":"Liu C","year":"2023","unstructured":"Liu C, Fang F, Kong Y, ElGabry EA. Tumor Area Positivity (TAP) score of programmed death-ligand 1 (PD-L1): a novel visual estimation method for combined tumor cell and immune cell scoring. Diagn Pathol. 2023, 18:48. 10.1186\/s13000-023-01318-8","journal-title":"Diagn Pathol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2025.100793","article-title":"Concordance between the PD-L1 tumor area positivity score and combined positive score for gastric or esophageal cancers treated with tislelizumab","volume":"38","author":"Moehler M","year":"2025","unstructured":"Moehler M, Yoon HH, Wagner DC, et al.. Concordance between the PD-L1 tumor area positivity score and combined positive score for gastric or esophageal cancers treated with tislelizumab. Mod Pathol. 2025, 38:100793. 10.1016\/j.modpat.2025.100793","journal-title":"Mod Pathol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-023-05595-0","article-title":"Concordance of assessments of four PD-L1 immunohistochemical assays in esophageal squamous cell carcinoma (ESCC)","volume":"150","author":"Wang X","year":"2024","unstructured":"Wang X, He J, Li J, et al.. Concordance of assessments of four PD-L1 immunohistochemical assays in esophageal squamous cell carcinoma (ESCC). J Cancer Res Clin Oncol. 2024, 150:43. 10.1007\/s00432-023-05595-0","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jncc.2023.11.003","article-title":"Concordance between four PD-L1 immunohistochemical assays and 22C3 pharmDx assay in esophageal squamous cell carcinoma in a multicenter study","volume":"4","author":"Xue L","year":"2024","unstructured":"Xue L, Li Y, Jiang L, et al.. Concordance between four PD-L1 immunohistochemical assays and 22C3 pharmDx assay in esophageal squamous cell carcinoma in a multicenter study. J Natl Cancer Cent. 2024, 4:162-8. 10.1016\/j.jncc.2023.11.003","journal-title":"J Natl Cancer Cent"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16061135","article-title":"Contrasting roles of programmed death-ligand 1 expression in tumor and stroma in prognosis of esophageal squamous cell carcinoma","volume":"16","author":"Murakami T","year":"2024","unstructured":"Murakami T, Booka E, Furuhashi S, et al.. Contrasting roles of programmed death-ligand 1 expression in tumor and stroma in prognosis of esophageal squamous cell carcinoma. Cancers (Basel). 2024, 16:1135. 10.3390\/cancers16061135","journal-title":"Cancers (Basel)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma","volume":"386","author":"Doki Y","year":"2022","unstructured":"Doki Y, Ajani JA, Kato K, et al.. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022, 386:449-62. 10.1056\/NEJMoa2111380","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun JM","year":"2021","unstructured":"Sun JM, Shen L, Shah MA, et al.. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021, 398:759-71. 10.1016\/S0140-6736(21)01234-4","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105854","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study","volume":"10","author":"Metges JP","year":"2025","unstructured":"Metges JP, Kato K, Sun JM, et al.. Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study. ESMO Open. 2025, 10:105854. 10.1016\/j.esmoop.2025.105854","journal-title":"ESMO Open"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.12836","article-title":"Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial","volume":"326","author":"Luo H","year":"2021","unstructured":"Luo H, Lu J, Bai Y, et al.. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial. JAMA. 2021, 326:916-25. 10.1001\/jama.2021.12836","journal-title":"JAMA"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2024.05.008","article-title":"Final analysis of camrelizumab plus chemotherapy for untreated advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st trial","volume":"5","author":"He M","year":"2024","unstructured":"He M, Wang Z, Lu J, et al.. Final analysis of camrelizumab plus chemotherapy for untreated advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st trial. Med. 2024, 5:1137-1149.e3. 10.1016\/j.medj.2024.05.008","journal-title":"Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068714","article-title":"Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial","volume":"377","author":"Lu Z","year":"2022","unstructured":"Lu Z, Wang J, Shu Y, et al.. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial. BMJ. 2022, 377:e068714. 10.1136\/bmj-2021-068714","journal-title":"BMJ"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00108-0","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study","volume":"24","author":"Xu J","year":"2023","unstructured":"Xu J, Kato K, Raymond E, et al.. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2023, 24:483-95. 10.1016\/S1470-2045(23)00108-0","journal-title":"Lancet Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.02.007","article-title":"Toripalimab plus chemotherapy in treatment-na\u00efve, advanced esophageal squamous cell carcinoma (JUPITER-06): a multi-center phase 3 trial","volume":"40","author":"Wang ZX","year":"2022","unstructured":"Wang ZX, Cui C, Yao J, et al.. Toripalimab plus chemotherapy in treatment-na\u00efve, advanced esophageal squamous cell carcinoma (JUPITER-06): a multi-center phase 3 trial. Cancer Cell. 2022, 40:277-288.e3. 10.1016\/j.ccell.2022.02.007","journal-title":"Cancer Cell"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.777686","article-title":"Efficacy and safety of immune checkpoint inhibitor in advanced esophageal squamous cell carcinoma: a meta-analysis","volume":"11","author":"Gu YM","year":"2021","unstructured":"Gu YM, Shang QX, Zhuo Y, et al.. Efficacy and safety of immune checkpoint inhibitor in advanced esophageal squamous cell carcinoma: a meta-analysis. Front Oncol. 2021, 11:777686. 10.3389\/fonc.2021.777686","journal-title":"Front Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.958783","article-title":"Comparative efficacy and toxicity of immune checkpoint inhibitors in combination with or without chemotherapy treatment for advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis","volume":"12","author":"Ma Y","year":"2022","unstructured":"Ma Y, Xin Y, Su D, et al.. Comparative efficacy and toxicity of immune checkpoint inhibitors in combination with or without chemotherapy treatment for advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis. Front Oncol. 2022, 12:958783. 10.3389\/fonc.2022.958783","journal-title":"Front Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1369848","article-title":"Efficacy and safety of first-line immune checkpoint inhibitor combination therapies in patients with advanced esophageal squamous cell carcinoma: a network meta-analysis","volume":"14","author":"Wang C","year":"2024","unstructured":"Wang C, Cai T, Wei J, Huang Y, Xiao L, Li T, Qin Z. Efficacy and safety of first-line immune checkpoint inhibitor combination therapies in patients with advanced esophageal squamous cell carcinoma: a network meta-analysis. Front Oncol. 2024, 14:1369848. 10.3389\/fonc.2024.1369848","journal-title":"Front Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.5816","article-title":"Effectiveness of immune checkpoint inhibitors in patients with advanced esophageal squamous cell carcinoma: a meta-analysis including low PD-L1 subgroups","volume":"9","author":"Yap DW","year":"2023","unstructured":"Yap DW, Leone AG, Wong NZ, Zhao JJ, Tey JC, Sundar R, Pietrantonio F. Effectiveness of immune checkpoint inhibitors in patients with advanced esophageal squamous cell carcinoma: a meta-analysis including low PD-L1 subgroups. JAMA Oncol. 2023, 9:215-24. 10.1001\/jamaoncol.2022.5816","journal-title":"JAMA Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231221339","article-title":"Current evidence of PD-1 and PD-L1 immune checkpoint inhibitors for esophageal cancer: an updated meta-analysis and synthesis of ongoing clinical trials","volume":"16","author":"Zafar S","year":"2024","unstructured":"Zafar S, Shehzadi R, Dawood H, Maqbool M, Sarfraz A, Sarfraz Z. Current evidence of PD-1 and PD-L1 immune checkpoint inhibitors for esophageal cancer: an updated meta-analysis and synthesis of ongoing clinical trials. Ther Adv Med Oncol. 2024, 16:17588359231221339. 10.1177\/17588359231221339","journal-title":"Ther Adv Med Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2026.104176","article-title":"Cross-trial interpretation of programmed death ligand-1 thresholds in advanced oesophageal squamous cell carcinoma requires caution","volume":"55","author":"Xue Y","year":"2026","unstructured":"Xue Y, Yan J. Cross-trial interpretation of programmed death ligand-1 thresholds in advanced oesophageal squamous cell carcinoma requires caution. Clin Oncol (R Coll Radiol). 2026, 55:104176. 10.1016\/j.clon.2026.104176","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30626-6","article-title":"Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Kato K","year":"2019","unstructured":"Kato K, Cho BC, Takahashi M, et al.. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019, 20:1506-17. 10.1016\/S1470-2045(19)30626-6","journal-title":"Lancet Oncol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0985","article-title":"Three-year follow-up and response-survival relationship of nivolumab in previously treated patients with advanced esophageal squamous cell carcinoma (ATTRACTION-3)","volume":"28","author":"Okada M","year":"2022","unstructured":"Okada M, Kato K, Cho BC, et al.. Three-year follow-up and response-survival relationship of nivolumab in previously treated patients with advanced esophageal squamous cell carcinoma (ATTRACTION-3). Clin Cancer Res. 2022, 28:3277-86. 10.1158\/1078-0432.CCR-21-0985","journal-title":"Clin Cancer Res"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01888","article-title":"Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer","volume":"38","author":"Kojima T","year":"2020","unstructured":"Kojima T, Shah MA, Muro K, et al.. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol. 2020, 38:4138-48. 10.1200\/JCO.20.01888","journal-title":"J Clin Oncol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s10388-021-00877-3","article-title":"Second-line pembrolizumab versus chemotherapy in Japanese patients with advanced esophageal cancer: subgroup analysis from KEYNOTE-181","volume":"19","author":"Muro K","year":"2022","unstructured":"Muro K, Kojima T, Moriwaki T, et al.. Second-line pembrolizumab versus chemotherapy in Japanese patients with advanced esophageal cancer: subgroup analysis from KEYNOTE-181. Esophagus. 2022, 19:137-45. 10.1007\/s10388-021-00877-3","journal-title":"Esophagus"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30110-8","article-title":"Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study","volume":"21","author":"Huang J","year":"2020","unstructured":"Huang J, Xu J, Chen Y, et al.. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2020, 21:832-42. 10.1016\/S1470-2045(20)30110-8","journal-title":"Lancet Oncol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.698732","article-title":"Comparison of PD-1 inhibitors in patients with advanced esophageal squamous cell carcinoma in the second-line setting","volume":"11","author":"Zhou YX","year":"2021","unstructured":"Zhou YX, Chen P, Sun YT, Zhang B, Qiu MZ. Comparison of PD-1 inhibitors in patients with advanced esophageal squamous cell carcinoma in the second-line setting. Front Oncol. 2021, 11:698732. 10.3389\/fonc.2021.698732","journal-title":"Front Oncol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01926","article-title":"Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): a randomized phase III study","volume":"40","author":"Shen L","year":"2022","unstructured":"Shen L, Kato K, Kim SB, et al.. Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): a randomized phase III study. J Clin Oncol. 2022, 40:3065-76. 10.1200\/JCO.21.01926","journal-title":"J Clin Oncol"},{"key":"ref28","unstructured":"September 26, 2024. Meeting of the Oncologic Drugs Advisory Committee Meeting Announcement. U.S. Food and Drug Administration. (2024). Accessed: July 31, 2026: https:\/\/www.fda.gov\/advisory-committees\/advisory-committee-calendar\/september-26-2024-meeting-oncologic-drugs-advisor...."},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly RJ","year":"2021","unstructured":"Kelly RJ, Ajani JA, Kuzdzal J, et al.. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021, 384:1191-203. 10.1056\/NEJMoa2032125","journal-title":"N Engl J Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03064-w","article-title":"Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO\/NCCES01 trial","volume":"30","author":"Qin J","year":"2024","unstructured":"Qin J, Xue L, Hao A, et al.. Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO\/NCCES01 trial. Nat Med. 2024, 30:2549-57. 10.1038\/s41591-024-03064-w","journal-title":"Nat Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03115-9","article-title":"First-line tislelizumab plus chemotherapy for esophageal squamous cell carcinoma with programmed death-ligand 1 expression \u2265 1%: a retrospective analysis of RATIONALE-306","volume":"42","author":"Xu J","year":"2025","unstructured":"Xu J, Kato K, Hubner R, et al.. First-line tislelizumab plus chemotherapy for esophageal squamous cell carcinoma with programmed death-ligand 1 expression \u2265 1%: a retrospective analysis of RATIONALE-306. Adv Ther. 2025, 42:2269-84. 10.1007\/s12325-025-03115-9","journal-title":"Adv Ther"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.4032","article-title":"Global, randomized, phase III study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced\/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): minimum 3-year survival follow-up","volume":"42","author":"Yoon HH","year":"2024","unstructured":"Yoon HH, Kato K, Raymond E, et al.. Global, randomized, phase III study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced\/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): minimum 3-year survival follow-up. J Clin Oncol. 2024, 42:4032. 10.1200\/JCO.2024.42.16_suppl.4032","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/523624-evolving-role-of-immunotherapy-in-advanced-esophageal-squamous-cell-carcinoma-are-programmed-death-ligand-1-pd-l1-cutoffs-still-relevant","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T07:19:34Z","timestamp":1786864774000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/523624-evolving-role-of-immunotherapy-in-advanced-esophageal-squamous-cell-carcinoma-are-programmed-death-ligand-1-pd-l1-cutoffs-still-relevant"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,16]]},"references-count":32,"URL":"https:\/\/doi.org\/10.7759\/cureus.114584","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,16]]}}}